INmune Bio, Inc. (NASDAQ:INMB) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET

Company Participants

David Moss - Chief Financial Officer

RJ Tesi - Chief Executive Officer

Mark Lowdell - Chief Scientific Officer

Conference Call Participants

Tom Shrader - BTIG

Daniel Carlson - Tailwinds Research

Operator

Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note today's event is being recorded.

I would now like to turn the conference over to David Moss, Chief Financial Officer. Please go ahead sir.

David Moss

Thank you, and good afternoon everybody. We thank you for joining us for the call for INmune Bio's first quarter 2023 financial results. With me on the call is Dr. RJ Tesi, CEO of INmune Bio; and Dr. Mark Lowdell, Chief Scientific Officer of INmune Bio who will provide an update on INKmune, our memory-like natural killer cell oncology platform.

Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those forward-looking statements.

Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings including our most recent quarterly filing with the SEC. There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information events or circumstances.

With that behind us, now I'd like to turn the call over to Dr. RJ Tesi, CEO of INmune Bio. RJ?

RJ Tesi

Thank you, David, and thank you everyone for joining the call. I will arrange my remarks to highlight the key takeaways for the first quarter and the subsequent period and also provide updates on our platform programs. I will start by reviewing developments in XPro, with XPro, the DN-TNF program and then hand the call to Mark Lowdell, our CSO who will speak about the developments in INKmune, before I pass it back to David to discuss financial results and provide an update on upcoming milestones. Then we will move to Q&A.